Diebold Nixdorf vs NCR Voyix
DBD and VYX side by side, both in computer and office equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBD and VYX compare
Diebold Nixdorf is the larger company, worth 1.3 times as much as NCR Voyix ($1.9B against $1.4B).
On earnings, NCR Voyix is cheaper: it trades at 15.4× trailing earnings, against 26.7× for Diebold Nixdorf.
Diebold Nixdorf grew revenue faster over the last twelve months (6.3% versus −8.6% for NCR Voyix).
NCR Voyix keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with 2.0% at Diebold Nixdorf.
NCR Voyix scores higher on the StockData Score (10 against 8 for Diebold Nixdorf), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBD | VYX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $1.4B |
| Share price | $57.04 | $10.45 |
| Change, 1 year | −12.2% | −7.8% |
| Change, 5 years | – | −74.4% |
| Beta (5Y) | 0.99 | 1.26 |
| Employees | 20K | 14K |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 4 | 6 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 26.7× | 15.4× (better) |
| P/S | 0.5× (better) | 0.6× |
| P/B | 2.0× | 1.5× (better) |
| EV/EBITDA | 8.0× (better) | 8.3× |
| FCF yield | – | −1.7% |
| Fair value | $91.07 | $21.00 |
| Margin of safety | 37.4% | 50.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.3% (better) | −8.6% |
| Revenue growth, 5Y average | −0.50% (better) | −15.4% |
| Net income growth (TTM) | 51.6% | – |
| EPS growth (TTM) | 56.2% | – |
| Profitability | ||
| Gross margin | 25.0% | – |
| Operating margin | 5.4% (better) | 2.4% |
| Net margin | 2.0% | 4.9% (better) |
| FCF margin | – | −1.00% |
| Return on equity | 7.5% | 13.2% (better) |
| Return on invested capital | 8.1% (better) | 3.3% |
| Financial health | ||
| Debt / equity | 1.01 (better) | 1.16 |
| Net debt / EBITDA | 2.28 (better) | 3.01 |
| Interest coverage | 2.2× (better) | 0.9× |
| Current ratio | 1.27 (better) | 1.11 |
| Altman Z-score | 1.84 (better) | 1.26 |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 10.8% (better) | 2.3% |
| Shareholder yield | 10.8% (better) | 2.3% |
| Ownership | ||
| Held by institutions | 116% | 117% |
| Held by insiders | 58.9% | 0.79% |
| Insider net buying, 12 months | −$126M | −$105K (better) |
| Short interest, % of float | 23.0% | – |
Go deeper
- DBD stock overview
- DBD income statement
- DBD valuation and score
- VYX stock overview
- VYX income statement
- VYX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.